Impact of intracoronary injection of CD133+ bone marrow stem cells on coronary atherosclerotic progression in patients with STEMI: A COMPARE-AMI IVUS substudy

Fuyu Qiu, Akiko Maehara, Ramez El Khoury, Philippe Généreux, Laura LaSalle, Gary S. Mintz, Nicolas Noiseux, Denis Claude Roy, François Gobeil, Louis Mathieu Stevens, François Reeves, Guy Leclerc, Alain Rivard, Samer Mansour

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objectives Adverse effects of intracoronary injection of stem cells on in-stent restenosis and atherosclerotic progression remain unclear. We sought to evaluate the adverse effects of intracoronary injection of CD133+ cells on in-stent restenosis and atherosclerotic progression in the infarct-related and contralateral arteries using serial intravascular ultrasound (IVUS) analysis. Methods Baseline and 4-month follow-up IVUS images were obtained from 17 patients treated with intracoronary stem cell injection and 20 placebo patients after primary percutaneous coronary intervention in the COMPARE-AMI trial. In the infarct-related artery, the stented segment, 5mm proximal and distal reference segments, and proximal and distal nonstented segments were analyzed every 1 mm; the entire segment of a contralateral artery was also analyzed every 1 mm. Results In the infarct-related artery analysis, the median percentage of in-stent neointimal hyperplasia (12.1 vs. 7.6%, P=0.95), the reduction in the minimum lumen area (MLA; -1.6 vs. -1.5mm2, P=0.97), and the MLA at follow-up (4.3 vs. 5.3mm2, P=0.21) were found to be similar between the stem cell and placebo groups. Changes in proximal and distal nonstented segment lumen areas and plaque burden were also similar between the stem cell and placebo groups; however, there was a decrease in the maximum arc of the attenuated plaque behind the stent from baseline to follow-up in the placebo group (P=0.004), but not in the stem cell group. In the contralateral artery, there were no differences in changes in MLA, plaque burden, or attenuated plaque between stem cell and placebo patients. Conclusion Intracoronary injection of CD133+ bone marrow stem cells has no IVUS-detectable effect on neointimal hyperplasia or atherosclerosis progression in either infarct-related or contralateral arteries.

Original languageEnglish (US)
Pages (from-to)5-12
Number of pages8
JournalCoronary Artery Disease
Volume27
Issue number1
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Bone Marrow Cells
Stem Cells
Arteries
Injections
Placebos
Stents
Hyperplasia
Percutaneous Coronary Intervention
ST Elevation Myocardial Infarction
Atherosclerosis

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Qiu, Fuyu ; Maehara, Akiko ; Khoury, Ramez El ; Généreux, Philippe ; LaSalle, Laura ; Mintz, Gary S. ; Noiseux, Nicolas ; Roy, Denis Claude ; Gobeil, François ; Stevens, Louis Mathieu ; Reeves, François ; Leclerc, Guy ; Rivard, Alain ; Mansour, Samer. / Impact of intracoronary injection of CD133+ bone marrow stem cells on coronary atherosclerotic progression in patients with STEMI : A COMPARE-AMI IVUS substudy. In: Coronary Artery Disease. 2016 ; Vol. 27, No. 1. pp. 5-12.
@article{81002a6ff7814d1783dd4b0099e51e73,
title = "Impact of intracoronary injection of CD133+ bone marrow stem cells on coronary atherosclerotic progression in patients with STEMI: A COMPARE-AMI IVUS substudy",
abstract = "Objectives Adverse effects of intracoronary injection of stem cells on in-stent restenosis and atherosclerotic progression remain unclear. We sought to evaluate the adverse effects of intracoronary injection of CD133+ cells on in-stent restenosis and atherosclerotic progression in the infarct-related and contralateral arteries using serial intravascular ultrasound (IVUS) analysis. Methods Baseline and 4-month follow-up IVUS images were obtained from 17 patients treated with intracoronary stem cell injection and 20 placebo patients after primary percutaneous coronary intervention in the COMPARE-AMI trial. In the infarct-related artery, the stented segment, 5mm proximal and distal reference segments, and proximal and distal nonstented segments were analyzed every 1 mm; the entire segment of a contralateral artery was also analyzed every 1 mm. Results In the infarct-related artery analysis, the median percentage of in-stent neointimal hyperplasia (12.1 vs. 7.6{\%}, P=0.95), the reduction in the minimum lumen area (MLA; -1.6 vs. -1.5mm2, P=0.97), and the MLA at follow-up (4.3 vs. 5.3mm2, P=0.21) were found to be similar between the stem cell and placebo groups. Changes in proximal and distal nonstented segment lumen areas and plaque burden were also similar between the stem cell and placebo groups; however, there was a decrease in the maximum arc of the attenuated plaque behind the stent from baseline to follow-up in the placebo group (P=0.004), but not in the stem cell group. In the contralateral artery, there were no differences in changes in MLA, plaque burden, or attenuated plaque between stem cell and placebo patients. Conclusion Intracoronary injection of CD133+ bone marrow stem cells has no IVUS-detectable effect on neointimal hyperplasia or atherosclerosis progression in either infarct-related or contralateral arteries.",
author = "Fuyu Qiu and Akiko Maehara and Khoury, {Ramez El} and Philippe G{\'e}n{\'e}reux and Laura LaSalle and Mintz, {Gary S.} and Nicolas Noiseux and Roy, {Denis Claude} and Fran{\cc}ois Gobeil and Stevens, {Louis Mathieu} and Fran{\cc}ois Reeves and Guy Leclerc and Alain Rivard and Samer Mansour",
year = "2016",
month = "1",
day = "1",
doi = "10.1097/MCA.0000000000000302",
language = "English (US)",
volume = "27",
pages = "5--12",
journal = "Coronary Artery Disease",
issn = "0954-6928",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

Qiu, F, Maehara, A, Khoury, RE, Généreux, P, LaSalle, L, Mintz, GS, Noiseux, N, Roy, DC, Gobeil, F, Stevens, LM, Reeves, F, Leclerc, G, Rivard, A & Mansour, S 2016, 'Impact of intracoronary injection of CD133+ bone marrow stem cells on coronary atherosclerotic progression in patients with STEMI: A COMPARE-AMI IVUS substudy', Coronary Artery Disease, vol. 27, no. 1, pp. 5-12. https://doi.org/10.1097/MCA.0000000000000302

Impact of intracoronary injection of CD133+ bone marrow stem cells on coronary atherosclerotic progression in patients with STEMI : A COMPARE-AMI IVUS substudy. / Qiu, Fuyu; Maehara, Akiko; Khoury, Ramez El; Généreux, Philippe; LaSalle, Laura; Mintz, Gary S.; Noiseux, Nicolas; Roy, Denis Claude; Gobeil, François; Stevens, Louis Mathieu; Reeves, François; Leclerc, Guy; Rivard, Alain; Mansour, Samer.

In: Coronary Artery Disease, Vol. 27, No. 1, 01.01.2016, p. 5-12.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Impact of intracoronary injection of CD133+ bone marrow stem cells on coronary atherosclerotic progression in patients with STEMI

T2 - A COMPARE-AMI IVUS substudy

AU - Qiu, Fuyu

AU - Maehara, Akiko

AU - Khoury, Ramez El

AU - Généreux, Philippe

AU - LaSalle, Laura

AU - Mintz, Gary S.

AU - Noiseux, Nicolas

AU - Roy, Denis Claude

AU - Gobeil, François

AU - Stevens, Louis Mathieu

AU - Reeves, François

AU - Leclerc, Guy

AU - Rivard, Alain

AU - Mansour, Samer

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Objectives Adverse effects of intracoronary injection of stem cells on in-stent restenosis and atherosclerotic progression remain unclear. We sought to evaluate the adverse effects of intracoronary injection of CD133+ cells on in-stent restenosis and atherosclerotic progression in the infarct-related and contralateral arteries using serial intravascular ultrasound (IVUS) analysis. Methods Baseline and 4-month follow-up IVUS images were obtained from 17 patients treated with intracoronary stem cell injection and 20 placebo patients after primary percutaneous coronary intervention in the COMPARE-AMI trial. In the infarct-related artery, the stented segment, 5mm proximal and distal reference segments, and proximal and distal nonstented segments were analyzed every 1 mm; the entire segment of a contralateral artery was also analyzed every 1 mm. Results In the infarct-related artery analysis, the median percentage of in-stent neointimal hyperplasia (12.1 vs. 7.6%, P=0.95), the reduction in the minimum lumen area (MLA; -1.6 vs. -1.5mm2, P=0.97), and the MLA at follow-up (4.3 vs. 5.3mm2, P=0.21) were found to be similar between the stem cell and placebo groups. Changes in proximal and distal nonstented segment lumen areas and plaque burden were also similar between the stem cell and placebo groups; however, there was a decrease in the maximum arc of the attenuated plaque behind the stent from baseline to follow-up in the placebo group (P=0.004), but not in the stem cell group. In the contralateral artery, there were no differences in changes in MLA, plaque burden, or attenuated plaque between stem cell and placebo patients. Conclusion Intracoronary injection of CD133+ bone marrow stem cells has no IVUS-detectable effect on neointimal hyperplasia or atherosclerosis progression in either infarct-related or contralateral arteries.

AB - Objectives Adverse effects of intracoronary injection of stem cells on in-stent restenosis and atherosclerotic progression remain unclear. We sought to evaluate the adverse effects of intracoronary injection of CD133+ cells on in-stent restenosis and atherosclerotic progression in the infarct-related and contralateral arteries using serial intravascular ultrasound (IVUS) analysis. Methods Baseline and 4-month follow-up IVUS images were obtained from 17 patients treated with intracoronary stem cell injection and 20 placebo patients after primary percutaneous coronary intervention in the COMPARE-AMI trial. In the infarct-related artery, the stented segment, 5mm proximal and distal reference segments, and proximal and distal nonstented segments were analyzed every 1 mm; the entire segment of a contralateral artery was also analyzed every 1 mm. Results In the infarct-related artery analysis, the median percentage of in-stent neointimal hyperplasia (12.1 vs. 7.6%, P=0.95), the reduction in the minimum lumen area (MLA; -1.6 vs. -1.5mm2, P=0.97), and the MLA at follow-up (4.3 vs. 5.3mm2, P=0.21) were found to be similar between the stem cell and placebo groups. Changes in proximal and distal nonstented segment lumen areas and plaque burden were also similar between the stem cell and placebo groups; however, there was a decrease in the maximum arc of the attenuated plaque behind the stent from baseline to follow-up in the placebo group (P=0.004), but not in the stem cell group. In the contralateral artery, there were no differences in changes in MLA, plaque burden, or attenuated plaque between stem cell and placebo patients. Conclusion Intracoronary injection of CD133+ bone marrow stem cells has no IVUS-detectable effect on neointimal hyperplasia or atherosclerosis progression in either infarct-related or contralateral arteries.

UR - http://www.scopus.com/inward/record.url?scp=84983098050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983098050&partnerID=8YFLogxK

U2 - 10.1097/MCA.0000000000000302

DO - 10.1097/MCA.0000000000000302

M3 - Article

C2 - 26340545

AN - SCOPUS:84983098050

VL - 27

SP - 5

EP - 12

JO - Coronary Artery Disease

JF - Coronary Artery Disease

SN - 0954-6928

IS - 1

ER -